Cargando…

Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial

BACKGROUND: Atypical antipsychotics are widely prescribed, yet have been associated with weight gain and metabolic syndrome. AIM: To study the effect of adjunct low-dose aripiprazole on weight and metabolic parameters of subjects on atypical antipsychotics (olanzapine, clozapine or risperidone). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Bhanu, Chee, Kok-Seng, Neo, Li-Qi, Tang, Charmaine, Hariram, Jayaraman, Tan, Geoffrey Chern-Yee, Verma, Swapna, Basu, Sutapa, Appan, Deva-Priya, Ting, Chan-Chun, Abdin, Edimansyah, Lee, Jimmy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504280/
https://www.ncbi.nlm.nih.gov/pubmed/34646440
http://dx.doi.org/10.1177/20451253211046765
_version_ 1784581300741472256
author Gupta, Bhanu
Chee, Kok-Seng
Neo, Li-Qi
Tang, Charmaine
Hariram, Jayaraman
Tan, Geoffrey Chern-Yee
Verma, Swapna
Basu, Sutapa
Appan, Deva-Priya
Ting, Chan-Chun
Abdin, Edimansyah
Lee, Jimmy
author_facet Gupta, Bhanu
Chee, Kok-Seng
Neo, Li-Qi
Tang, Charmaine
Hariram, Jayaraman
Tan, Geoffrey Chern-Yee
Verma, Swapna
Basu, Sutapa
Appan, Deva-Priya
Ting, Chan-Chun
Abdin, Edimansyah
Lee, Jimmy
author_sort Gupta, Bhanu
collection PubMed
description BACKGROUND: Atypical antipsychotics are widely prescribed, yet have been associated with weight gain and metabolic syndrome. AIM: To study the effect of adjunct low-dose aripiprazole on weight and metabolic parameters of subjects on atypical antipsychotics (olanzapine, clozapine or risperidone). METHODS: The study was carried out as an open-label trial with a fixed dose of 5 mg aripiprazole added to the patient’s current antipsychotic for 12 weeks. The primary outcome measure was mean change in weight, while secondary outcome measures included change in waist circumference; fasting blood glucose; HbA1c; triglycerides; total, HDL and LDL cholesterol levels; functioning; and neurocognition. RESULTS: For the overall study (n = 55), there was no significant effect of adjunct aripiprazole on the weight of the subjects. However, the clozapine group achieved significant weight loss (p = 0.002) and also had significant improvements in total cholesterol (p < 0.001), HDL (p = 0.016), LDL (p = 0.044) and triglyceride levels (p = 0.038). The olanzapine group had significant improvement in triglycerides (p = 0.001), and other metabolic parameters for this group showed improvement trends, but did not reach statistical significance. The risperidone group did not show any significant improvement in weight or metabolic parameters. CONCLUSIONS: The study adds support to the adjunctive use of aripiprazole to clozapine for weight loss and improvement in metabolic profile, and for reduction in cardiometabolic risk for patients on olanzapine. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02949752
format Online
Article
Text
id pubmed-8504280
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85042802021-10-12 Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial Gupta, Bhanu Chee, Kok-Seng Neo, Li-Qi Tang, Charmaine Hariram, Jayaraman Tan, Geoffrey Chern-Yee Verma, Swapna Basu, Sutapa Appan, Deva-Priya Ting, Chan-Chun Abdin, Edimansyah Lee, Jimmy Ther Adv Psychopharmacol Original Research BACKGROUND: Atypical antipsychotics are widely prescribed, yet have been associated with weight gain and metabolic syndrome. AIM: To study the effect of adjunct low-dose aripiprazole on weight and metabolic parameters of subjects on atypical antipsychotics (olanzapine, clozapine or risperidone). METHODS: The study was carried out as an open-label trial with a fixed dose of 5 mg aripiprazole added to the patient’s current antipsychotic for 12 weeks. The primary outcome measure was mean change in weight, while secondary outcome measures included change in waist circumference; fasting blood glucose; HbA1c; triglycerides; total, HDL and LDL cholesterol levels; functioning; and neurocognition. RESULTS: For the overall study (n = 55), there was no significant effect of adjunct aripiprazole on the weight of the subjects. However, the clozapine group achieved significant weight loss (p = 0.002) and also had significant improvements in total cholesterol (p < 0.001), HDL (p = 0.016), LDL (p = 0.044) and triglyceride levels (p = 0.038). The olanzapine group had significant improvement in triglycerides (p = 0.001), and other metabolic parameters for this group showed improvement trends, but did not reach statistical significance. The risperidone group did not show any significant improvement in weight or metabolic parameters. CONCLUSIONS: The study adds support to the adjunctive use of aripiprazole to clozapine for weight loss and improvement in metabolic profile, and for reduction in cardiometabolic risk for patients on olanzapine. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02949752 SAGE Publications 2021-10-09 /pmc/articles/PMC8504280/ /pubmed/34646440 http://dx.doi.org/10.1177/20451253211046765 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Gupta, Bhanu
Chee, Kok-Seng
Neo, Li-Qi
Tang, Charmaine
Hariram, Jayaraman
Tan, Geoffrey Chern-Yee
Verma, Swapna
Basu, Sutapa
Appan, Deva-Priya
Ting, Chan-Chun
Abdin, Edimansyah
Lee, Jimmy
Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
title Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
title_full Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
title_fullStr Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
title_full_unstemmed Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
title_short Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
title_sort effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504280/
https://www.ncbi.nlm.nih.gov/pubmed/34646440
http://dx.doi.org/10.1177/20451253211046765
work_keys_str_mv AT guptabhanu effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT cheekokseng effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT neoliqi effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT tangcharmaine effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT hariramjayaraman effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT tangeoffreychernyee effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT vermaswapna effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT basusutapa effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT appandevapriya effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT tingchanchun effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT abdinedimansyah effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial
AT leejimmy effectofaripiprazoleasanadjuncttoatypicalantipsychoticsonweightandmetabolicprofilea12weekopenlabeltrial